(VXZ) iPath Series SP500 VIX - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US06746P6135 • Trading--Miscellaneous
VXZ: Futures Contracts, VIX Index, Mid-Term Exposure
The iPath® Series B S&P 500® VIX Mid-Term Futures ETN (BATS:VXZ) is a debt instrument designed to provide investors with exposure to the performance of the S&P 500® VIX Mid-Term Futures™ Index. This index offers a rolling long position in the fourth and fifth month VIX futures contracts, which are selected based on the shape of the VIX futures curve. The ETN does not provide direct exposure to the VIX index itself but instead tracks the performance of VIX futures contracts with maturities between four and seven months. This approach is intended to reduce the impact of contango, a common issue in VIX futures trading, where longer-dated contracts trade at a premium to shorter-dated ones. By focusing on mid-term futures, the ETN aims to capture the volatility expectations of the market over a slightly longer horizon compared to short-term VIX products. The product is traded on the BATS exchange under the ticker symbol VXZ.
3-Month Forecast: Based on the current technical and fundamental data, the iPath® Series B S&P 500® VIX Mid-Term Futures ETN (VXZ) is expected to experience moderate volatility over the next three months. The average volume of 14,120 shares over the past 20 days indicates relatively low liquidity, which could lead to larger price swings in response to market movements. The last price of 56.69 is trading above the 20-day and 50-day simple moving averages (SMA) of 52.14 and 51.12, respectively, but below the 200-day SMA of 50.95. This suggests that the ETN may be in a transitional phase, potentially gearing up for a trend reversal or continuation. The average true range (ATR) of 1.23 reflects moderate volatility, which is relatively stable compared to other VIX-related products. On the fundamental side, the assets under management (AUM) of $34.94 million are relatively small, which could impact the ETNs ability to track its underlying index efficiently, especially during periods of high market stress. Overall, the ETN is likely to remain sensitive to broader market sentiment and the shape of the VIX futures curve, with potential for both upside and downside movements depending on macroeconomic conditions and risk appetite.
Additional Sources for VXZ ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
VXZ ETF Overview
Market Cap in USD | 35m |
Category | Trading--Miscellaneous |
TER | 0.89% |
IPO / Inception | 2018-01-17 |
VXZ ETF Ratings
Growth 5y | -68.7% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -12 |
Analysts | - |
Fair Price Momentum | 45.80 USD |
Fair Price DCF | - |
VXZ Dividends
No Dividends PaidVXZ Growth Ratios
Growth Correlation 3m | 63% |
Growth Correlation 12m | -2% |
Growth Correlation 5y | -92.2% |
CAGR 5y | -16.89% |
CAGR/Max DD 5y | -0.25 |
Sharpe Ratio 12m | -0.44 |
Alpha | 0.72 |
Beta | -1.72 |
Volatility | 29.45% |
Current Volume | 18.3k |
Average Volume 20d | 27.4k |
As of March 25, 2025, the stock is trading at USD 53.13 with a total of 18,329 shares traded.
Over the past week, the price has changed by -2.28%, over one month by +1.34%, over three months by +6.77% and over the past year by -3.62%.
No, based on ValueRay Analyses, iPath Series SP500 VIX (BATS:VXZ) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -68.70 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VXZ as of March 2025 is 45.80. This means that VXZ is currently overvalued and has a potential downside of -13.8%.
iPath Series SP500 VIX has no consensus analysts rating.
According to ValueRays Forecast Model, VXZ iPath Series SP500 VIX will be worth about 49.5 in March 2026. The stock is currently trading at 53.13. This means that the stock has a potential downside of -6.91%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 49.5 | -6.9% |